
Top articles of the year on Specialty Pharmacy Times.


Top articles of the year on Specialty Pharmacy Times.

Pharmacists improve care for patients in many settings, especially for diabetes.

Many organizations use quality indicators to determine how well their clinicians work individually and together to ensure patients receive evidence-based care.

Anti-vascular endothelial growth factor agents are the criterion standard for diabetic macular edema.

Platypus and echidna venom contains a stable form of a hormone that could be used to improve diabetes treatment.

Hospitalization and death is more likely among individuals with diabetes when they contract influenza than when healthy individuals do, and so influenza vaccination uptake is an important area of scrutiny.

This year's top news regarding pharmacy benefit managers.

This year's top 10 top articles about diabetes.

Jardiance reducea the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease.

Clonidine topical gel was not more effective than placebo in reducing pain from diabetic neuropathy.

After 4 weeks of moderate exercise, rat models with diabetes had improved memory function.

Clonidine topical gel fails to achieve desired outcome in reducing pain from diabetic neuropathy.

The placenta diverts blood flow away from the brain in fetuses of mothers with diabetes.

Officials with the FDA have expanded the use of Dexcom’s G5 Mobile Continuous Glucose Monitoring System to allow for replacement of fingerstick blood glucose testing for diabetes treatment decisions in people 2 years of age and older with diabetes,

Tresiba is now indicated to treat patients with diabetes as young as 1-year-old.

Some diabetes drugs are thought to cause weight loss through the hypothalamus, but other parts of the brain may be involved.

Patients with diabetes buying Eli Lilly insulin can potentially save 40% off retail price.

Novo Nordisk submitted the supplemental New Drug Application (sNDA) based on the results of the BEGIN Young 1 trial, a multi-national, 26-week, phase 3b, randomized, controlled, clinical trial.

Researchers discovered a statistically significant link between diabetes and all-cause mortality.

Top articles of the week from The American Journal of Pharmacy Benefits.

FDA-approved drug could reduce the risk of death in adults with diabetes and cardiovascular disease.

Top news of the day from across the health care landscape.

Jardiance could reduce the risk of death in adults with diabetes and cardiovascular disease.

Some conditions associated with type 2 diabetes may significantly impair renal function.

Top news of the day from across the health care landscape.